These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23121277)

  • 1. New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.
    Dastiridou A; Kalogeropoulos C; Brazitikos P; Symeonidis C; Androudi S
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):543-55. PubMed ID: 23121277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with biologics of pregnant patients with rheumatic diseases.
    Ostensen M; Förger F
    Curr Opin Rheumatol; 2011 May; 23(3):293-8. PubMed ID: 21346578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
    Vinet E; Pineau C; Gordon C; Clarke AE; Bernatsky S
    Arthritis Rheum; 2009 May; 61(5):587-92. PubMed ID: 19404999
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic therapies for inflammatory eye disease.
    Lim L; Suhler EB; Smith JR
    Clin Exp Ophthalmol; 2006; 34(4):365-74. PubMed ID: 16764659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab for treatment of birdshot chorioretinopathy.
    Sobrin L; Huang JJ; Christen W; Kafkala C; Choopong P; Foster CS
    Arch Ophthalmol; 2008 Feb; 126(2):186-91. PubMed ID: 18268208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.
    Prey S; Robert PY; Drouet M; Sparsa A; Roux C; Bonnetblanc JM; Bédane C
    Acta Derm Venereol; 2007; 87(1):74-5. PubMed ID: 17225020
    [No Abstract]   [Full Text] [Related]  

  • 11. Alopecia areata universalis complicating daclizumab therapy for uveitis.
    Rosenstein AK; Machler BC; Rosenstein ED
    Cutis; 2014 May; 93(5):E13-6. PubMed ID: 24897146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
    Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE; Kalden JR
    Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary immune deficiencies associated with biological therapeutics.
    Lee SJ; Yedla P; Kavanaugh A
    Curr Allergy Asthma Rep; 2003 Sep; 3(5):389-95. PubMed ID: 12906774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [2/2 The other biotherapies].
    Fournel C; Medjoub M; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Nov; (720):59-61. PubMed ID: 18376755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.